|
| 36608320 | A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. | Blood | 2023 |
| 37760637 | Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial. | Cancers (Basel) | 2023 |
| 37756525 | Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy. | Blood | 2023 |
| 37593101 | Editorial: New emerging functions of transcription factors and RNA-binding proteins in the development of hematological malignancies. | Front Oncol | 2023 |
| 37600821 | Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma. | Front Immunol | 2023 |
| 37190302 | Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma. | Cancers (Basel) | 2023 |
| 37423893 | Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells. | Br J Haematol | 2023 |
| 37035206 | The RNA helicase DDX3 and its role in c-MYC driven germinal center-derived B-cell lymphoma. | Front Oncol | 2023 |
| 37296874 | Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma-A Critical Toxicity Evaluation in the Modern Treatment Era. | Cancers (Basel) | 2023 |
| 37091981 | Dose-dependent effect of GFI1 expression in the reconstitution and the differentiation capacity of HSCs. | Front Cell Dev Biol | 2023 |
| 34792186 | Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells. | Br J Haematol | 2022 |
| 35804097 | GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia. | Leukemia | 2022 |
| 35795041 | Inhibiting PI3K-AKT-mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells. | Front Oncol | 2022 |
| 36428605 | Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario. | Cancers (Basel) | 2022 |
| 36457063 | Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. | J Hematol Oncol | 2022 |
| 35928862 | The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma. | Front Oncol | 2022 |
| 36328040 | Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. | Lancet Haematol | 2022 |
| 35954410 | Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis. | Cancers (Basel) | 2022 |
| 36003783 | Presence of the <i>GFI1-36N</i> single nucleotide polymorphism enhances the response of <i>MLL-AF9</i> leukemic cells to CDK4/6 inhibition. | Front Oncol | 2022 |
| 35158832 | Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2022 |
| 35158754 | High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in <i>MLL/AF9</i> Acute Myeloid Leukemia. | Cancers (Basel) | 2022 |
| 35251992 | Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. | Front Oncol | 2022 |
| 35077804 | A synthetic covalent ligand of the C/EBPβ transactivation domain inhibits acute myeloid leukemia cells. | Cancer Lett | 2022 |
| 34017122 | The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. | Nat Immunol | 2021 |
| 33809431 | Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM. | Cancers (Basel) | 2021 |
| 33779471 | Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy. | Leuk Lymphoma | 2021 |
| 35008835 | Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS). | Int J Mol Sci | 2021 |
| 35008207 | Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity. | Cancers (Basel) | 2021 |
| 34760702 | Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis. | Front Oncol | 2021 |
| 32444892 | Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma. | Ann Hematol | 2020 |
| 30679800 | LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. | Leukemia | 2019 |
| 29925903 | Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice. | Leukemia | 2019 |
| 31555592 | Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies. | Front Oncol | 2019 |
| 31508375 | Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications. | Front Oncol | 2019 |
| 30837671 | Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. | Leukemia | 2019 |
| 29326122 | Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome. | Haematologica | 2018 |
| 29674496 | GFI1 is required for <i>RUNX1/ETO</i> positive acute myeloid leukemia. | Haematologica | 2018 |
| 29651020 | GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. | Nat Commun | 2018 |
| 28074069 | Myelodysplastic syndromes and bone loss in mice and men. | Leukemia | 2017 |
| 29147018 | Enforced GFI1 expression impedes human and murine leukemic cell growth. | Sci Rep | 2017 |
| 27080012 | GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome. | Exp Hematol | 2016 |
| 26601782 | Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia. | Leukemia | 2016 |
| 27390361 | Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. | Haematologica | 2016 |
| 27467586 | Threshold Levels of Gfi1 Maintain E2A Activity for B Cell Commitment via Repression of Id1. | PLoS One | 2016 |
| 27216773 | Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. | Exp Hematol | 2016 |
| 26805453 | Virus-specific antibodies allow viral replication in the marginal zone, thereby promoting CD8(+) T-cell priming and viral control. | Sci Rep | 2016 |
| 26765577 | A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A. | J Clin Endocrinol Metab | 2016 |
| 27007114 | High Frequencies of Anti-Host Reactive CD8+ T Cells Ignore Non-Hematopoietic Antigen after Bone Marrow Transplantation in a Murine Model. | Cell Physiol Biochem | 2016 |
| 26847026 | GFI1 as a novel prognostic and therapeutic factor for AML/MDS. | Leukemia | 2016 |
| 26447191 | From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation. | Blood | 2015 |